Document:

EX-10.2

Exhibit 10.2

EXECUTIVE EMPLOYMENT AGREEMENT

     THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into effective March 6,
2009, by and between Wireless Ronin Technologies, Inc., a corporation duly organized and existing
under the laws of the State of Minnesota, with a place of business at 5929 Baker Road, Suite 475,
Minnetonka, Minnesota 55345 (hereinafter referred to as the “Company”), and Darin McAreavey, a
natural person residing at 18373 Smith Court, Elk River, MN 55330 (hereinafter referred to as
“Executive”).

BACKGROUND OF AGREEMENT

	•	 	The Company desires to employ Executive as its Vice President and Chief Financial Officer,
and Executive desires to accept such employment.
	 
	•	 	This Agreement provides, among other things, for base compensation for Executive, a term of
employment and severance payments in the event Executive is terminated without Cause or by
reason of a Change of Control of the Company.
	 
	 	 	In consideration of the foregoing, the Company and Executive agree as follows:

ARTICLE 1

EMPLOYMENT

     1.01 Subject to the terms of Articles 3 and 6, the Company hereby agrees to employ Executive
pursuant to the terms of this Agreement, and Executive agrees to such employment as its Vice
President and Chief Financial Officer, and shall hold such title under the terms of this Agreement.
Executive’s primary place of employment shall be the Company’s executive offices at Minnetonka,
Minnesota.

     1.02 Executive shall generally have the authority, responsibilities, and such duties as are
customarily performed by the chief financial officer of a public company of similar size and
industry. Notwithstanding the foregoing, Executive shall also render such additional services and
duties within the scope of Executive’s experience and expertise as may be reasonably requested of
him from time to time by the Board and the Company’s chief executive officer. Further, the Board
of directors and chief executive officer of the Company may from time to time in its discretion
redefine the duties and responsibilites of Executive as they determine the needs of the Company’s
business warrant.

     1.03 Executive shall report to the chief executive officer of the Company and to the Board or
any committee thereof as the Board or chief executive officer shall direct, and shall generally be
subject to direction, orders and advice of the chief executive officer and the Board.

ARTICLE 2

BEST EFFORTS OF EXECUTIVE

     2.01 In his capacity as Chief Financial Officer, Executive shall use his best efforts and
abilities in the performance of his duties, services and responsibilities for the Company.

 

 

     2.02 During the term of his employment, Executive shall devote substantially all of his
business time and attention to the business of the Company and its subsidiaries and affiliates and
shall not engage in any substantial activity inconsistent with the foregoing, whether or not such
activity shall be engaged in for pecuniary gain, unless approved by the Board; provided, however,
that, to the extent such activities do not violate, or substantially interfere with his performance
of his duties, services and responsibilities under this Agreement, Executive may engage in such
activities.

ARTICLE 3

TERM AND NATURE OF EMPLOYMENT

     3.01 Executive’s employment hereunder shall be for an initial term beginning March 9, 2009,
and ending December 31, 2009. Neither the Company nor Executive shall be obligated to extend such
term of the employment relationship. The term of Executive’s employment shall automatically be
extended for successive one (1) year periods unless the Company or Executive elects not to extend
employment by giving written notice to the other not less than thirty (30) days prior to the end of
the initial term or any extension periods. The terms and conditions of this Agreement may be
amended from time to time with the consent of the Company and Executive. All such amendments shall
be effective when memorialized by a written agreement between the Company and Executive, following
approval by the Company’s Compensation Committee (the “Committee”).

ARTICLE 4

COMPENSATION AND BENEFITS

     4.01 During the initial term of employment hereunder, Executive shall be paid a base salary at
Executive’s current rate of One Hundred Eighty Two Thousand Five Hundred Dollars ($182,500) per
year (“Base Salary”), payable in accordance with the Company’s established pay periods, reduced by
all deductions and withholdings required by law and as otherwise specified by Executive. The
Company agrees to review Executive’s performance and compensation in 2009 and annually thereafter.
Executive’s Base Salary may be increased (but not decreased) in the sole discretion of the Board;
provided that Executive’s Base Salary may be reduced after any such increase in connection with
Company compensation reductions applied to all other senior executives of the Company. In the
event Executive’s employment shall for any reason terminate during the Term, Executive’s final
monthly Base Salary payment shall be made on a pro-rated basis as of the last day of the month in
which such employment terminated.

     4.02 During the term of employment, in addition to payments of Base Salary set forth above,
Executive may be eligible to participate in any performance-based cash bonus or equity award plan
for senior executives of the Company, based upon achievement of individual and/or Company goals
established by the Board or Committee. The extent of Executive’s participation in bonus plans
shall be within the discretion of the Company’s Board or Compensation Committee. Executive shall
be entitled to receive a target bonus of $40,000 to be paid by the Company if performance targets
are achieved under the terms of the Company’s senior executive bonus program in 2009.

2

 

     4.03 During the term of employment, Executive shall be entitled to participate in employee
benefit plans, policies, programs, perquisites and arrangements, as the same may be provided and
amended from time to time, that are provided generally to similarly situated executive employees of
the Company, to the extent Executive meets the eligibility requirements for any such plan, policy,
program, perquisite or arrangement.

     4.04 The Company shall reimburse Executive for all reasonable business expenses incurred by
Executive in carrying out Executive’s duties, services, and responsibilities under this Agreement.
Executive shall comply with generally applicable policies, practices and procedures of the Company
with respect to reimbursement for, and submission of expense reports, receipts or similar
documentation of, such expenses.

ARTICLE 5

VACATION AND LEAVE OF ABSENCE

     5.01 Executive shall be entitled to twenty-two (22) business days of paid time off (“PTO”) for
each twelve (12) months of employment, in addition to the Company’s normal holidays. PTO includes
sick days and leaves of absence. PTO will be scheduled taking into account the Executive’s duties
and obligations at the Company. All unused PTO shall be accumulated from year to year, in
accordance with the Company’s PTO Policy. PTO and sick leave and all other leaves of absence will
be taken in accordance with the Company’s stated personnel policies. Upon termination or
expiration of the Executive’s employment, Executive shall be entitled to compensation for any
accrued, unused PTO time in accordance with the Company’s PTO Policy as of date of termination.

ARTICLE 6

TERMINATION

     6.01 The Company may terminate Executive’s employment without Cause upon written notice to
Executive. In the event of a termination of Executive without Cause, including a termination by
Executive for Good Reason, Executive shall be entitled to receive: (i) the Severance Payment
provided in Section 7.01 and (ii) the bonus described in Section 7.03. For the purposes of this
Agreement, an election by the Company not to extend this Agreement pursuant to Section 3.01 shall
be deemed a termination without cause.

     6.02 Executive’s employment will terminate as of the date of the death or Disability of the
Executive. In the event of such termination, there shall be payable to Executive or Executive’s
estate or beneficiaries Base Salary earned through the date of death together with a pro-rata
portion of any bonus due Executive pursuant to any bonus plan or arrangement established or
mutually agreed-upon prior to termination, to the extent earned or performed based upon the
requirements or criteria of such plan or arrangement, as the Board shall in good faith determine.
Such pro-rated bonus shall be payable at the time and in the manner payable to other executives of
the Company who participate in such plan or arrangement. For purposes of this Agreement
“Disability” shall mean a determination by the Board of the Company of the inability of Executive
to perform substantially all of his duties and responsibilities under this Agreement due to
illness, injury, accident or condition of either a physical or psychological

3

 

nature, and such inability continues for an aggregate of ninety (90) days during any period of
three hundred and sixty-five (365) consecutive calendar days. Such determination shall be made in
good faith by the Board, the decision of which shall be conclusive and binding.

     6.03 Any other provision of this Agreement notwithstanding, the Company may terminate
Executive’s employment upon written notice specifying a termination date based on any of the
following events that constitute Cause:

     (a) Any conviction or nolo contendere plea by Executive to a felony, gross misdemeanor
or misdemeanor involving moral turpitude, or any public conduct by Executive that has or can
reasonably be expected to have a detrimental effect on the Company and the image of its
management;

     (b) Any act of material misconduct, willful and gross negligence, or material breach of
duty with respect to the Company, including, but not limited to, embezzlement, fraud,
dishonesty, nonpayment of an obligation owed to the Company, or material breach of a
fiduciary duty to the Company which results in harm or loss to the Company;

     (c) Any material breach of any material provision of this Agreement or of the Company’s
announced or written rules, codes or polices; provided, however, that such breach shall not
constitute Cause if Executive cures or remedies such breach within thirty (30) days after
written notice to Executive, without material harm or loss to the Company, unless (i) such
breach is part of a pattern of chronic breaches of the same, which may be evidenced by
reports or warning letters given by the Company to Executive; or (ii) such breach is of a
nature that it is deemed by the Board not to be curable, including situations where the
Board determines that harm or loss to the Company has already occurred or can reasonably be
expected to occur and cannot be eliminated by such cure.

     (d) Any act of insubordination by Executive; provided, however, an act of
insubordination by Executive shall not constitute Cause if Executive cures or remedies such
insubordination within thirty (30) days after written notice to Executive, without material
harm or loss to the Company, unless (i) such insubordination is a part of a pattern of
chronic insubordination, which may be evidenced by reports or warning letters given by the
Company to Executive; or (ii) such insubordination is of a nature that it is deemed by the
Board not to be curable, including situations where the Board determines that harm or loss
to the Company has already occurred or can reasonably be expected to occur and cannot be
eliminated by such cure.

     (e) Any unauthorized disclosure of any Company trade secret or confidential
information, or conduct constituting unfair competition with respect to the Company,
including inducing a party to breach a contract with the Company; or

     (f) A willful violation of federal or state securities laws or employment laws.

In making such determination of Cause, the Board shall act in good faith and give Executive a
reasonably detailed written notice and a reasonable opportunity to be heard on the issues at a
Board or Committee meeting. A resolution providing for the termination of Executive’s employment
for Cause must be approved by a majority of the members of the Board; provided,

4

 

however, that if Executive is a member of the Board, he shall not vote on the resolution shall not
be deemed to be a member of the Board for purposes of whether a majority of its members have
approved such termination. Executive’s employment shall be deemed terminated for Cause upon the
approval by the Board of a resolution terminating Executive’s employment for Cause unless a later
time or date is specified. For purposes of this Agreement, no act or failure by the Executive
shall be considered “willful” if such act is done by Executive in good faith in the belief that
such act is or was lawful and in the best interest of the Company or one or more of its businesses.
Nothing in this Section 6.03 shall be construed to prevent Executive from contesting the Board or
Committee’s determination that Cause exists. In the event of a termination for Cause, and not
withstanding any contrary provision otherwise stated, Executive shall receive only his Base Salary
earned through the date of termination.

     6.04 Executive may terminate his employment upon sixty (60) days prior written notice to the
Company for “Good Reason.” For purposes of this Agreement, “Good Reason” means any of the
following events or actions taken by the Company without Cause:

     (a) the Company or any of its subsidiaries reduces Executive’s Base Salary or base rate
of annual compensation, or otherwise changes benefits provided to Executive under
compensation and benefit plans, arrangements, policies and procedures to be as a whole
materially less favorable to Executive, other than reductions in Base Salary permitted under
Section 4.01;

     (b) without Executive’s express written consent, the Company or any of its subsidiaries
significantly reduces Executive’s job authority and responsibility, as the Company’s Chief
Financial Officer, except as permitted under Section 1.02;

     (c) without Executive’s express written consent, the Company or any of its subsidiaries
requires Executive to change the location of Executive’s job or office, to a location more
than fifty (50) miles from the location of Executive’s job or office immediately prior to
such required change;

     (d) a successor company fails or refuses to assume the Company’s obligations under this
Agreement; or

     (e) the Company or any successor company breaches any of the material provisions of
this Agreement.

If Executive intends to terminate this Agreement for Good Reason, Executive must give not less than
sixty (60) days written notice to the Company of the facts or events giving rise to Good Reason,
and must give such notice within ninety (90) days following the facts or event alleged to give rise
to Good Reason. The Company shall, within such sixty-day notice period, have the right to cure or
remedy events or any action or event constituting “Good Reason” within the meaning of this Section
6.04. The failure to give such notice shall be deemed a waiver of the right to terminate this
Agreement for Good Reason based on such fact or event.

     6.05 During the term of his employment and for 24 months after the date of Executive’s
termination of employment, (i) Executive shall not, directly or indirectly, make or publish any
disparaging statements (whether written or oral) regarding the Company or any of its affiliated
companies or businesses, or the affiliates, directors, officers, agents, principal

5

 

shareholders or customers of any of them and (ii) the Company’s directors and officers shall
not directly or indirectly, make or publish any disparaging statements (whether written or oral)
regarding Executive. Information which the Company’s directors, officers or Executive is required
to make or disclose regarding the other to comply with laws or regulations, or makes in a pleading
on the advice of litigation counsel, and information which the directors or officers need to
disclose for legitimate business reasons (for example disclosure to the Company’s insurers or
business associates), shall not constitute a disparaging statement.

     6.06 Upon any termination of Executive’s employment with the Company, Executive will
immediately return to the Company all equipment, property and documents of the Company, including,
specifically all property and documents containing any “Confidential Information” as described in
Section 8.01 of this Agreement.

     6.07 Upon any termination of Executive’s employment with the Company, Executive shall be
deemed to have resigned from all other positions he then holds as an officer, employee or director
or other independent contactor of the Company or any of its subsidiaries or affiliates, unless
otherwise agreed by the Company and Executive.

     6.08 The provisions of Sections 6.05 and 6.07 shall survive the termination of this Agreement.

ARTICLE 7

SEVERANCE PAYMENTS

     7.01 The Company, its successors or assigns, will pay Executive as severance pay (the
“Severance Payment”) an amount equal to six (6) months of the Executive’s monthly Base Salary for
full-time employment at the time of Executive’s termination:

     (a) if (i) there has been a Change of Control of the Company (as defined in Section
7.02), and (ii) Executive is an active and full-time employee at the time of the Change of
Control, and (iii) within twelve (12) months following the date of the Change of Control,
Executive’s employment is involuntarily terminated for any reason (including Good Reason (as
definition Section 6.04)), other than for Cause or death or disability; or

     (b) if Executive’s employment is terminated by the Company without Cause, or by
Executive for Good Reason.

Nothing in this Section 7.01 shall limit the authority of the Committee or Board to terminate
Executive’s employment in accordance with Section 6.03. Except as provided in Section 7.10 below,
payment of the Severance Payment pursuant to Section 7.01, less customary withholdings, shall be
made in equal monthly installments commencing on the thirtieth day following the Executive’s
termination or resignation and shall be made over the non-competition period specified in Section
9.01. No Severance shall be payable if Executive’s employment is terminated due to death or
Disability. Except as provided in Section 7.06, payment of the Severance Payment pursuant to
Section 7.01, less customary withholdings, shall be made in equal monthly installments commencing
on the thirtieth day following the Executive’s termination or resignation and shall be made over
the non-competition period specified in Section 9.01.

6

 

     7.02 For the purposes of this Agreement, “Change of Control” shall mean any one of the
following:

     (a) an acquisition by any individual, entity or group (within the meaning of Section
13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
of 50% or more of either: (1) the then outstanding Stock; or (2) the combined voting power
of the Company’s outstanding voting securities immediately after the merger or acquisition
entitled to vote generally in the election of directors; provided, however, that the
following acquisition shall not constitute a Change of Control: (i) any acquisition
directly from the Company; (ii) any acquisition by the Company or Subsidiary; (iii) any
acquisition by the trustee or other fiduciary of any employee benefit plan or trust
sponsored by the Company or a Subsidiary; or (iv) any acquisition by any corporation with
respect to which, following such acquisition, more than 50% of the Stock or combined voting
power of Stock and other voting securities of the Company is beneficially owned by
substantially all of the individuals and entities who were beneficial owners of Stock and
other voting securities of the Company immediately prior to the acquisition in substantially
similar proportions immediately before and after such acquisition; or

     (b) individuals who, as of the date of this Agreement, constitute the Board (the
“Incumbent Board”), cease to constitute a majority of the Board during any 12 month period.
Individuals nominated or whose nominations are approved by the Incumbent Board and
subsequently elected shall be deemed for this purpose to be members of the Incumbent Board;
or

     (c) approval by the shareholders of the Company of a reorganization, merger,
consolidation, liquidation, dissolution, sale or statutory exchange of Stock which changes
the beneficial ownership of Stock and other voting securities so that after the corporate
change the immediately previous owners of 50% of Stock and other voting securities do not
own 50% of the Company’s Stock and other voting securities either legally or beneficially;
or

     (d) the sale, transfer or other disposition of all substantially all of the Company’s
assets in a transaction with a third party, other than in connection with a joint venture or
similar transaction; or

     (e) a merger of the Company with another entity after which the pre-merger shareholders
of the Company own less than 50% of the stock of the surviving corporation.

     A “Change of Control” shall not be deemed to occur with respect to Executive if the
acquisition of a 50% or greater interest is by a group that includes the Executive, nor shall it be
deemed to occur if at least 50% of the Stock and other voting securities owned before the
occurrence are beneficially owned subsequent to the occurrence by a group that includes the
Executive.

     7.03 In addition to the Severance Payment payable pursuant to Section 7.01, the Company will
pay Executive a bonus (“Severance Bonus”) in lump sum within thirty (30) days

7

 

following a termination of employment pursuant to Section 7.01 an amount equal to Executive’s
bonus earned for the last fiscal year, but not to exceed Executive’s target bonus as set forth in
any bonus plan arrangement in which Executive participates at the time of termination of his
employment. Without limiting other payments which would not constitute “cash severance-type
benefits” hereunder, any cash settlement of stock options, accelerated vesting of stock options and
retirement, pension and other similar benefits shall not constitute “cash severance-benefits” for
purposes of this Section 7.03.

     7.04 If Executive becomes entitled to the Severance Payment pursuant to Section 7.01,
Executive shall be entitled to receive, if Executive is eligible to and elects to continue medical
coverage from the Company as provided by law (commonly referred to as the COBRA continuation
period), as part of his severance benefit, continued medical coverage under the Company’s medical
plan. The Company will pay the Company’s portion of contribution to monthly medical insurance
premiums paid at the time of termination of employee’s employment for such COBRA coverage for
Executive and his eligible dependents for a period ending on the earlier of one year following
termination, or until Executive is eligible to be covered by another plan providing medical
benefits to Executive. To receive such benefit, Executive must be eligible for COBRA coverage,
elect COBRA during the COBRA election period, and comply with all requirements to obtain such
coverage, to be eligible for coverage and for this benefit.

     7.05 All severance payments made under this Article (7), including those paid under Section
7.01, 7.02, 7.03 and 7.04, shall be conditioned upon the Executive’s signing and not rescinding a
separation agreement and release in a form acceptable to the Company, which agreement shall
include, at a minimum a full and general release of all claims to the greatest extent allowed by
applicable law, a covenant not to sue, and an agreement to be reasonably available for consultation
and assistance to the Company during any period in which severance is paid, and an agreement to
return to the Company all Company property and copies thereof in any form or media.

     7.06 Notwithstanding any other provision of this Agreement, the Company and Executive intend
that any payments, benefits or other provisions applicable to this Agreement comply with the payout
and other limitations and restrictions imposed under Section 409A of the Code (“Section 409A”), as
clarified or modified by guidance from the U.S. Department of Treasury or the Internal Revenue
Service – in each case if and to the extent Section 409A is otherwise applicable to this Agreement
and such compliance is necessary to avoid the penalties otherwise imposed under Section 409A. In
this connection, the Company and Executive agree that the payments, benefits and other provisions
applicable to this Agreement, and the terms of any deferral and other rights regarding this
Agreement, shall be deemed modified if and to the extent necessary to comply with the payout and
other limitations and restrictions imposed under Section 409A, as clarified or supplemented by
guidance from the U.S. Department of Treasury or the Internal Revenue Service – in each case if and
to the extent Section 409A is otherwise applicable to this Agreement and such compliance is
necessary to avoid the penalties otherwise imposed under Section 409A. The total severance benefit
payable to the Executive during the first six months following the Executive’s termination of
employment shall not exceed the lesser of two times the Executive’s annual compensation or the
amount specified in Section 409A of the Code ($490,000 in 2009). Any amounts that cannot be paid
because of this limitation shall be paid in a lump sum on the first day of the seventh month
following the Executive’s termination of employment. The remaining amount shall be paid in
installments for the duration

8

 

of the non-compete period. Notwithstanding the above, should the Executive terminate
employment for a Good Reason, that does not constitute an involuntary termination of employment
under Section 409A of the Code, no payment shall be made until the first day of the seventh month
following the Executive’s termination of employment. Any amounts that cannot be paid because of
this limitation shall be paid in a lump sum on the first day of the seventh month following the
Executive’s termination of employment.

     7.07 The Company may withhold from any amounts payable under this Agreement all federal,
state, city or other taxes required by applicable law to be withheld by the Company.

     7.08 The provisions of this Article 7 will be deemed to survive the termination of this
Agreement for the purposes of satisfying the obligations of the Company and Executive hereunder.

     7.09 The total severance benefit payable to the Executive during the first six months
following the Executive’s termination of employment shall not exceed the lesser of two times the
Executive’s annual compensation or the amount specified in Section 409A of the Code ($490,000 in
2009). Any amounts that cannot be paid because of this limitation shall be paid in a lump sum on
the first day of the seventh month following the Executive’s termination of employment. The
remaining amount shall be paid in installments for the duration of the non-compete period.
Notwithstanding the above, should the Executive terminate employment for a Good Reason, that does
not constitute an involuntary termination of employment under Section 409A of the Code, no payment
shall be made until the first day of the seventh month following the Executive’s termination of
employment. Any amounts that cannot be paid because of this limitation shall be paid in a lump sum
on the first day of the seventh month following the Executive’s termination of employment.

ARTICLE 8

NONDISCLOSURE AND INVENTIONS

     8.01 Except as permitted or directed by the Company or as may be required in the proper
discharge of Executive’s employment hereunder, Executive shall not, during his employment or at any
time thereafter, divulge, furnish or make accessible to anyone or use in any way any Confidential
Information of the Company. “Confidential Information” means any information or compilation of
information that the Executive learns or develops during the course of his/her employment that is
not generally known by persons outside the Company (whether or not conceived, originated,
discovered, or developed in whole or in part by Executive). Confidential Information includes but
is not limited to, the following types of information and other information of a similar nature
(whether or not reduced to writing), all of which Executive agrees constitutes the valuable trade
secrets of the Company: research, designs, development, know how, computer programs and processes,
marketing plans and techniques, existing and contemplated products and services, customer and
product names and related information, prices sales, inventory, personnel, computer programs and
related documentation, technical and strategic plans, and finances. Confidential Information also
includes any information of the foregoing nature that the Company treats as proprietary or
designates as Confidential Information, whether or not owned or developed by the Company.
“Confidential Information” does not include information that (a) is or becomes generally available
to the public

9

 

through no fault of Executive, (b) was known to Executive prior to its disclosure by the
Company, as demonstrated by files in existence at the time of the disclosure, (c) becomes known to
Executive, without restriction, from a source other than the Company, without breach of this
Agreement by Executive and otherwise not in violation of the Company’s rights, or (d) is explicitly
approved for release by written authorization of the Company.

     8.02 Executive acknowledges that all inventions, innovations, improvements, developments,
methods, designs, trade secrets, analyses, drawings, reports and all similar related information
(whether or not patentable) which relate to the Company’s or any of its subsidiaries’ actual or
anticipated business, research and development or existing products or services and which are
conceived, developed or made by Executive while employed by the Company or any of its subsidiaries
(“Work Product”) belong to the Company or such subsidiary. Executive shall promptly disclose such
Work Product to the Board of Directors of the Company and, at the Company’s expense, perform all
actions reasonably requested by the Board (whether during or after employment by the Company) to
establish and confirm such ownership (including, without limitation, assignments, consents, powers
of attorney and other instruments). For purposes of this Agreement, any Work Product or other
discoveries relating to the business of the Company or any subsidiaries on which Executive files or
claims a copyright or files a patent application, within one year after termination of employment
with the Company, shall be presumed to cover and be Work Product conceived or developed by
Executive in whole or in part during the term of his employment with the Company, subject to proof
to the contrary by good faith, written and duly corroborated records establishing that such Work
Product was conceived and made following termination of employment.

     Notwithstanding the foregoing, the Company advises Executive, and Executive understands and
agrees, that the foregoing does not apply to inventions or other discoveries for which no
equipment, supplies, facility or trade secret information of the Company was used and that was
developed entirely on Executive’s own time, and (a) that does not relate (i) directly to the
Company’s business, or (ii) to the Company’s actual or demonstrably anticipated business research
or development, or (b) that does not result from any work performed by Executive for the Company.

     8.03 In the event of a breach or threatened breach by Executive of the provisions of this
Article 8, the Company shall be entitled to an injunction restraining Executive from directly or
indirectly disclosing, disseminating, lecturing upon, publishing or using such confidential, trade
secret or proprietary information (whether in whole or in part) and restraining Executive from
rendering any services or participating with any person, firm, corporation, association or other
entity to whom such knowledge or information (whether in whole or in part) has been disclosed,
without the posting of a bond or other security. Nothing herein shall be construed as prohibiting
the Company from pursuing any other equitable or legal remedies available to it for such breach or
threatened breach, including the recovery of damages from Executive.

     8.04 Executive agrees that all notes, data, reference materials, documents, business plans,
business and financial records, computer programs, and other materials that in any way incorporate,
embody, or reflect any of the Confidential Information, whether prepared by Executive or others,
are the exclusive property of the Company, and Executive agrees to forthwith deliver to the Company
all such materials, including all copies or memorializations thereof, in Executive’s possession or
control, whenever requested to do so by the Company, and

10

 

in any event, upon termination of Executive’s employment with the Company.

     8.05 The Executive understands and agrees that any violation of this Article 8 while employed
by the Company may result in immediate disciplinary action by the Company, including termination of
employment for Cause.

     8.06 The provisions of this Article 8 shall survive termination of this Agreement
indefinitely.

ARTICLE 9

NON-COMPETITION, NON-INTERFERENCE AND NON-SOLICITATION

     9.01 In further consideration of the compensation to be paid to Executive hereunder, including
amounts payable to Executive as a Severance Payment, Executive acknowledges that in the course of
his employment with the Company he will become familiar, and during his employment with the Company
he has become familiar, with the Company’s trade secrets and other Confidential Information
concerning the Company and that his services have been and will be of a special, unique and
extraordinary value to the Company, and therefore, Executive agrees that, during the period of his
employment, and for a period of two years following the end of Executive’s employment term
specified in Section 3.01 or any extension thereof, he shall not directly or indirectly own any
interest in, manage, control, participate in, consult with, render services for, or in any manner
engage in any business competing with the business of the Company, its subsidiaries or affiliates,
as defined below and as such businesses exist or are in the process during the period of his
employment on the date of termination or the expiration of the period his employment, within any
geographical area in which the Company or its subsidiaries or affiliates engage or have defined
plans to engage in such businesses. Nothing herein shall prevent Executive from being a passive
owner of not more than 2% of the outstanding stock of any class of a corporation which is publicly
traded, so long as Executive has no participation in the business of such corporation. For the
purposes of this Agreement, “business” or “business of the Company” means, with respect to and
including the Company and its subsidiaries or affiliates, the design, development, marketing and
sale of digital signage products and solutions.

     9.02 Executive agrees that during the term of his employment and for a period of one (1) year
after the termination of Executive’s employment he will not directly or indirectly (i) in any way
interfere or attempt to interfere with the Company’s relationships with any of its current or
potential customers, vendors, investors, business partners, or (ii) employ or attempt to employ any
of the Company’s employees on behalf of any other entity, whether or not such entity competes with
the Company.

     9.03 Executive agrees that breach by him of the provisions of this Article 9 will cause the
Company irreparable harm that is not fully remedied by monetary damages. In the event of a breach
or threatened breach by Executive of the provisions of this Article 9, the Company shall be
entitled to an injunction restraining Executive from directly or indirectly competing or recruiting
as prohibited herein, without posting a bond or other security, and, if the Company is successful
in establishing a breach, to its reasonable attorneys’ fees and costs. Nothing herein shall be
construed as prohibiting the Company from pursuing any other equitable or legal remedies available
to it for such breach or threatened breach, including the recovery of damages

11

 

from Executive.

     9.04 The Executive understands and agrees that any violation of this Article 9 while employed
by the Company may result in immediate disciplinary action by the Company, including termination of
employment for Cause.

     9.05 The obligations contained in this Article 9 shall survive the termination of this
Agreement as described in this Article 9.

ARTICLE 10

MISCELLANEOUS

     10.01 Governing Law. This Agreement shall be governed and construed according to the
laws of the State of Minnesota without regard to conflicts of law provisions. The Company and
Executive agree that if any action is brought pursuant to this Agreement that is not otherwise
resolved by arbitration pursuant to Section 10.06, such dispute shall be resolved only in the
District Court of Hennepin County, Minnesota, or the United States District Court for Minnesota,
and each party hereto unconditionally (a) submits for itself in any proceeding relating to this
Agreement, or for recognition and enforcement of any judgment in respect thereof, to the exclusive
jurisdiction of the Hennepin County, Minnesota District Courts or the United States Federal
District Court for Minnesota, and agrees that all claims in respect to any such proceeding shall be
heard and determined in Hennepin County, Minnesota, Minnesota District Court or, to the extent
permitted by law, in such federal court, (b) consents that any such proceeding may and shall be
brought in such courts and waives any objection that it may now or thereafter have to the venue or
jurisdiction of any such proceeding in any such court or that such proceeding was brought in an
inconvenient court and agrees not to plead or claim the same; waives all right to trial by jury in
any proceeding (whether based on contract, tort or otherwise) arising out of or relating to this
Agreement, or its performance under or the enforcement of this Agreement; (d) agrees that service
of process in any such proceeding may be effected by mailing a copy of such process by registered
or certified mail (or any substantially similar form of mail), postage prepaid, to such party at
its address as provided in Section 10.08; and (e) agrees that nothing in this Agreement shall
affect the right to effect service of process in any other manner permitted by the laws of the
State of Minnesota.

     10.02 Successors. This Agreement is personal to Executive and Executive may not
assign or transfer any part of his rights or duties hereunder, or any compensation due to him
hereunder, to any other person or entity. This Agreement may be assigned by the Company. The
Company shall require any successor or assignee, whether direct or indirect, by purchase, merger,
consolidation or otherwise, of all or substantially all the business or assets of the Company,
expressly and unconditionally to assume and agree to perform the Company’s obligations under this
Agreement, in the same manner and to the same extent that the Company would be required to perform
if no such succession or assignment had taken place. In such event, the term “Company,” as used in
this Agreement, shall mean the Company as defined above and any successor or assignee to the
business or assets which by reason hereof becomes bound by the terms and provisions of this
Agreement.

     10.03 Waiver. The waiver by the Company of the breach or nonperformance of any

12

 

provision of this Agreement by Executive will not operate or be construed as a waiver of any
future breach or nonperformance under any such provision or any other provision of this Agreement
or any similar agreement with any other Executive.

     10.04 Entire Agreement; Modification. This Agreement supersedes, revokes and replaces
any and all prior oral or written understandings, if any, between the parties relating to the
subject matter of this Agreement. The parties agree that this Agreement: (a) is the entire
understanding and agreement between the parties; and (b) is the complete and exclusive statement of
the terms and conditions thereof, and there are no other written or oral agreements in regard to
the subject matter of this Agreement. Except for modifications described in Section 3.01 and
Section 4.01, this Agreement shall not be changed or modified except by a written document signed
by the parties hereto.

     10.05 Severability and Blue Penciling. To the extent that any provision of this
Agreement shall be determined to be invalid or unenforceable as written, the validity and
enforceability of the remainder of such provision and of this Agreement shall be unaffected. If
any particular provision of this Agreement shall be adjudicated to be invalid or unenforceable, the
Company and Executive specifically authorize the tribunal making such determination to edit the
invalid or unenforceable provision to allow this Agreement, and the provisions thereof, to be valid
and enforceable to the fullest extent allowed by law or public policy.

     10.06 Arbitration. Any dispute, claim or controversy arising under this Agreement
shall, at the request of any party hereto be resolved by binding arbitration in Hennepin County,
Minnesota by a single arbitrator selected by the Company and Executive, with arbitration governed
by The United States Arbitration Act (Title 9, U.S. Code); provided, however, that a dispute, claim
or controversy shall be subject to adjudication by a court in any proceeding against the Company or
Executive involving third parties (in addition to the Company or Executive). Such arbitrator shall
be a disinterested person who is either an attorney, retired judge or labor relations arbitrator.
In the event employer and Executive are unable to agree upon such arbitrator, the arbitrator shall,
upon petition by either the Company or Executive, be designated by a judge of the Hennepin County
District Court. The arbitrator shall have the authority to make awards of damages as would any
court in Minnesota having jurisdiction over a dispute between employer and Executive, except that
the arbitrator may not make an award of exemplary damages or consequential damages. In addition,
the Company and Executive agree that all other matters arising out of Executive’s employment
relationship with the Company shall be arbitrable, unless otherwise restricted by law.

     (a) In any arbitration proceeding, each party shall pay the fees and expenses of its or
his own legal counsel.

     (b) The arbitrator, in his or her discretion, shall award legal fees and expenses and
costs of the arbitration, including the arbitrator’s fee, to a party who substantially
prevails in its claims in such proceeding.

     (c) Notwithstanding this Section 10.06, in the event of alleged noncompliance or
violation, as the case may be, of Sections 8 or 9 of this Agreement, the Company may
alternatively apply to a court of competent jurisdiction for a temporary restraining order,
injunctive and/or such other legal and equitable remedies as may be appropriate.

13

 

     10.07 Legal Fees. If any contest or dispute shall arise between the Company and
Executive regarding any provision of this Agreement, and such dispute results in court proceedings
or arbitration, a party that prevails with respect to a claim brought and pursued in connection
with such dispute, shall be entitled to recover its legal fees and expenses reasonably incurred in
connection with such dispute. Such reimbursement shall be made as soon as practicable following
the resolution of the dispute (whether or not appealed) to the extent a party receives documented
evidence of such fees and expenses.

     10.08 Notices. For purposes of this Agreement, notices and all other communications
provided for herein shall be in writing and shall be deemed to have been duly given when personally
delivered or may send by certified mail, return receipt requested, postage prepaid, addressed to
Executive at his residence address appearing on the records of the Company and to the Company at
its then current executive offices to the attention of the Board. All notices and communications
shall be deemed to have been received on the date of delivery thereof or on the third business day
after the mailing thereof, except that notice of change of address shall be effective only upon
actual receipt. No objection to the method of delivery may be made if the written notice or other
communication is actually received.

     10.09 Survival. The provisions of this Article 10 shall survive the termination of
this Agreement, indefinitely.

     IN WITNESS WHEREOF the following parties have executed the above instrument the day and year
first above written.

	 	 	 	 	 	 	 
	 	 	WIRELESS RONIN TECHNOLOGIES, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By
	 	/s/ James C. Granger
 

	 	 
	 

	 	Its:
	 	President and CEO	 	 
	 
	 	 	 	 	 	 
	 	 	EXECUTIVE	 	 
	 
	 	 	 	 	 	 
	 	 	/s/ Darin McAreavey	 	 
	 	 	 	 	 
	 	 	Darin McAreavey	 	 

14EX-10.32

Exhibit 10.32

AMENDMENT AND WAIVER AGREEMENT

     This Amendment and Waiver Agreement (“Agreement”) is made as of the 6th day of March, 2009 by
and among Allion Healthcare, Inc. (“Allion”), Biomed Healthcare, Inc., Access Therapeutics, Inc.,
Atlas Respiratory Services, Inc., Biomed California, Inc. (“BioMed CA”), Biomed Florida, Inc.,
Biomed Kansas, Inc., Biomed PA, Inc., Biomed Pharmaceuticals, Inc., Biomed Texas, Inc., Access
Healthcare Services, LLC, Moms Pharmacy of Brooklyn, Inc., Moms Pharmacy, Inc., Moms Pharmacy,
Inc., Mail Order Meds of Florida, LLC, Oris Health, Inc., North American Home Health Supply, Inc.,
Medicine Made Easy and Specialty Pharmacies, Inc. (together with Allion and Biomed CA,
collectively, the “Borrowers” and each individually referred to as a “Borrower”), the financial
institutions listed as lenders on the signature pages hereto (collectively, the “Lenders”), and CIT
Healthcare LLC, as administrative agent (“Agent”).

Background

     A. Borrowers, Agent and Lenders are parties to that certain Credit and Guaranty Agreement
dated as of April 4, 2008 (as amended, modified, restated and supplemented from time to time,
including by that certain letter agreement executed by Borrowers, Agent and Lenders dated June 25,
2008, the “Credit Agreement”) pursuant to which Borrowers established certain financing
arrangements with Lenders. All capitalized terms not otherwise defined herein shall have the
meaning ascribed thereto in the Credit Agreement.

     B. Borrowers acknowledge that Borrowers failed to promptly notify Agent of the Application
Denial (as defined below) pursuant to Section 6.03 of the Credit Agreement and (ii) that the
Application Denial may have resulted in certain misrepresentations being made with respect to those
representations contained in Sections 5.07(b), 5.16, 5.26, 5.28 and 5.29(ii) as they may be
impacted by the denial by the Department of Health Care Services of the State of California
(“DHCS”) of the change of ownership application submitted by BioMed CA with respect to a pharmacy
acquired by BioMed in July, 2007 (the “Application Denial”) corresponding to the change of
ownership filed by Allion and BioMed CA as the case may be on July 18, 2007 and April 29, 2008
respectively.

     C. Borrowers have requested and Agent and Lenders have agreed to waive the consequences of
such failures and possible misrepresentations relating to the Application Denial and amend certain
terms and conditions of the Credit Agreement pursuant to the terms and conditions of this
Agreement.

     NOW, THEREFORE, with the foregoing Background incorporated by reference and made a part hereof
and intending to be legally bound, the parties agree as follows:

     1. Waivers. Upon the effectiveness of this Agreement, Agent and Lenders hereby waive
(a) Borrowers’ failure to notify Agent of the Application Denial under Section 6.03 of the Credit
Agreement and (b) any misrepresentations under Sections 5.07(b), 5.16, 5.26, 5.28 and 5.29(ii) of
the Credit Agreement solely with respect to any matters relating to and impacted by the Application
Denial; provided, however, the waiver in this clause (b) shall not apply to any representation
regarding any event, circumstance or condition which now or in the future could reasonably be
expected to have a Material Adverse Effect. Such waiver shall in no way constitute a waiver of any
other failure to comply with any provision of the Credit Agreement which may have

 

 

occurred but which is not specifically referenced in this Agreement, nor shall it obligate
Agent or any Lender to provide any waiver of, or other accommodation with respect to, any other
such failure (whether similar or dissimilar, including, without limitation, (i) a failure to comply
with Section 6.03 and/or Section 9.01(d) of the Credit Agreement, (ii) any Events of Default
resulting from a final non-appealable judgment from a court of competent jurisdiction upholding
and/or affirming (or failing to overturn or reverse in full) the Application Denial and/or (iii)
any other actions taken by or on behalf of any Governmental Authority, including, without
limitation, DHCS or any intermediary against the Borrowers, or any of them, including, without
limitation, any action or request seeking repayment, disgorgement or recoupment of any amounts paid
by or on behalf of DHCS or any intermediary or imposing any fines or penalties as a result of, or
in connection with, the Application Denial).

     2. Default. Upon the effectiveness of this Agreement, the following shall constitute
an Event of Default under the Credit Agreement: any request or demand for repayment, recoupment or
disgorgement in an amount in excess of $2,000,000 relating to, or in connection with, the
Application Denial is paid, made, requested or assessed against any Loan Party; provided, that,
such request, demand or assessment is based on a final non-appealable judgment, determination or
finding from a court or other Governmental Authority (including, without limitation, DHCS or any
intermediary).

     3. Representations and Warranties. Each Borrower represents and warrants to Agent and
each Lender that:

          (a) Assuming the effectiveness of this Agreement, all warranties and representations made to
Lender under the Credit Agreement and the Loan Documents are true and correct as to the date
hereof.

          (b) Except for the enrollment in MediCal for BioMed CA and the related matter regarding a
change of ownership in connection with the Target Merger that has been consolidated with it
(“BioMed MediCal Matter”), each Borrower that seeks reimbursement under Medicare or Medicaid is
currently enrolled and participates in the Medicare and state Medicaid programs of the
jurisdictions in which such Borrower operates.

          (c) No penalty, sanction, fine or restriction has been currently assessed or imposed upon any
Borrower, nor has any claim for repayment, disgorgement or recoupment of amounts paid to or on
behalf of BioMed CA or any other Borrower been asserted or threatened, in connection with or
related to the BioMed MediCal Matter or any other matter, in each case which could reasonably be
expected to have a Material Adverse Effect.

          (d) Neither the BioMed MediCal Matter, nor any fine, sanction or penalty that may be hereafter
imposed (should BioMed CA be unsuccessful in its appeal of the Application Denial) if paid or
successfully appealed, has negatively affected or impaired, or would reasonably be likely to
negatively affect or impair: (i) any Permit for any of BioMed CA’s pharmacies or the Permit of any
other pharmacy, supplier or provider owned, managed or operated by any of the Borrowers or its
Affiliates or (ii) the right or ability of BioMed CA or any other pharmacy, supplier or provider
owned, managed or operated by any of the Borrowers or its Affiliates to participate in Medicare,
any state Medicaid program or any other payor program in which such Borrower currently

2

 

participates in or may, in the future participate in, or otherwise participated in on the
Closing Date, in either case, which could reasonably be expected to have a Material Adverse Effect.

          (e) Except for the BioMed MediCal Matter, there is no pending or, to Borrowers’ knowledge,
threatened, action or proceeding challenging or contesting any Permit or right of any of the
Borrowers to participate in Medicare, any state Medicaid program or any other payor program and
Borrowers are not aware of any facts or events that would give any governmental agency the right or
authority to contest or challenge any of the foregoing, in each case, which could reasonably be
expected to have a Material Adverse Effect.

          (f) The execution and delivery by each Borrower of this Agreement, and all other documents,
instruments, and agreements executed in connection with this Agreement and the performance by it of
the transactions herein contemplated, (i) are and will be within its powers, (ii) have been
authorized by all necessary organizational action, and (iii) are not and will not be in
contravention of any order of any court or other agency of government, of law or any other
indenture, agreement or undertaking to which such Borrower is a party or by which the property of
such Borrower is bound, or be in conflict with, result in a breach of, or constitute (with due
notice and/or lapse of time) a default under any such indenture, agreement or undertaking or result
in the imposition of any lien, charge or encumbrance of any nature on any of the properties of such
Borrower.

          (g) This Agreement, all other documents, instruments and agreements executed in connection
with this Agreement and any assignment, instrument, document, or agreement executed and delivered
in connection herewith, will be valid, binding, and enforceable in accordance with its respective
terms, except as enforceability may be limited by applicable Debtor Relief Laws or by equitable
principles relating to enforceability.

          (h) Assuming the effectiveness of this Agreement, no Default or Event of Default has occurred
and is continuing under the Credit Agreement or any of the other Loan Documents.

     4. Effectiveness Conditions. This Agreement shall be effective upon satisfaction of
the following conditions precedent (all documents to be in form and substance satisfactory to Agent
and Agent’s counsel in its sole and absolute discretion):

          (a) Execution and delivery by Borrowers of this Agreement;

          (b) No Default or Event of Default after giving effect hereto shall have occurred and be
continuing under the Credit Documents;

          (c) All warranties and representations made to Lender under the Credit Agreement, the Loan
Documents and hereunder are true and correct as to the date hereof; and

          (d) Payment by Borrowers of any and all costs, fees and expenses of Agent (including, without
limitation, reasonable attorneys’ fees) in connection with this Agreement and the transaction
contemplated hereby.

     5. Default. Without limiting the terms of the Credit Agreement and for avoidance of
doubt, it shall be an Event of Default under the Credit Agreement if (a) any representation or

3

 

warranty made by Borrowers, or any of them, in this Agreement shall be incorrect or misleading
in any material respect at any time made or deemed made or (b) Borrowers, or any of them, fail to
perform or observe any covenant or agreement set forth in this Agreement.

     6. Confirmation of Indebtedness. Borrowers hereby acknowledge and confirm that as of
the close of business on March 5, 2009, Borrowers are indebted to Agent and Lenders, without
defense, setoff, claim or counterclaim under the Loan Documents, in the aggregate principal amount
of $51,946,346.74, comprised of (a) $17,821,346.74 with respect to the Revolving Loans and (b)
$34,125,000.00 with respect to the Term Loan plus all fees, costs and expenses (including
attorneys’ fees) incurred to date in connection with, and as payable under the Loan Documents.

     7. Ratification of Credit Documents. Except as expressly set forth herein, all of the
terms and conditions of the Credit Agreement and Loan Documents are hereby ratified and confirmed
and continue unchanged and in full force and effect. All references to the Credit Agreement shall
mean the Credit Agreement as modified by this Agreement.

     8. Collateral. Each Borrower hereby confirms and agrees that all security interests
and liens granted to Agent, for the benefit of Lenders, continue in full force and effect and shall
continue to secure the Obligations.

     9. Release. As further consideration for Agent’s and Lenders’ agreement to grant the
accommodations set forth herein, Borrowers hereby waive and release and forever discharge Agent and
each Lender and each of their respective officers, directors, attorneys, agents and employees
(collectively, “Released Parties”) from any liability, damage, claim, loss or expense of any kind
that Borrowers, or any of them, may now or hereafter have against the Released Parties, or any of
them, arising out of or relating to the Obligations, this Agreement, the Credit Agreement or the
Loan Documents, but only to the extent of any circumstance, action, cause or matter arising at any
time on or prior to the date that this Agreement is executed by all parties.

     10. Governing Law. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES
HERETO SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK
WITHOUT REGARD TO ANY CONFLICTS OF LAWS PRINCIPLES THEREOF THAT WOULD CALL FOR THE APPLICATION OF
THE LAWS OF ANY OTHER JURISDICTION.

     11. Waiver of Right to Trial by Jury. EACH PARTY TO THIS AGREEMENT HEREBY EXPRESSLY
WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER
THIS AGREEMENT OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES
HERETO OR ANY OF THEM WITH RESPECT TO ANY CREDIT DOCUMENT, OR THE TRANSACTIONS RELATED THERETO, IN
EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER FOUNDED IN CONTRACT OR TORT OR
OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE
OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS AGREEMENT MAY
FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE
CONSENT OF THE SIGNATORIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

4

 

     12. Signatories: Each individual signatory hereto represents and warrants that he or
she is duly authorized to execute this Agreement on behalf of his or her principal and that he or
she executes the Agreement in such capacity and not as a party.

     13. Duplicate Originals: Two or more duplicate originals of this Agreement may be
signed by the parties, each of which shall be an original but all of which together shall
constitute one and the same instrument. This Agreement may be executed in counterparts, all of
which counterparts taken together shall constitute one completed fully executed document.
Signature by facsimile or PDF shall bind the parties hereto.

5

 

     IN WITNESS WHEREOF, the parties have executed this Agreement the day and year first above
written.

	 	 	 
	Borrowers:

	 	ALLION HEALTHCARE, INC.

	 

	 	BIOMED HEALTHCARE, INC.

	 

	 	ACCESS THERAPEUTICS, INC.

	 

	 	ATLAS RESPIRATORY SERVICES, INC.

	 

	 	BIOMED CALIFORNIA, INC.

	 

	 	BIOMED FLORIDA, INC.
	 

	 	BIOMED KANSAS, INC.
	 

	 	BIOMED PA, INC.
	 

	 	BIOMED PHARMACEUTICALS, INC.
	 

	 	BIOMED TEXAS, INC.
	 

	 	ACCESS HEALTHCARE SERVICES, LLC
	 

	 	MOMS PHARMACY OF BROOKLYN, INC.
	 

	 	MOMS PHARMACY, INC., a New York corporation
	 

	 	MOMS PHARMACY, INC., a California corporation
	 

	 	MAIL ORDER MEDS OF FLORIDA, LLC
	 

	 	ORIS HEALTH, INC.
	 

	 	NORTH AMERICAN HOME HEALTH SUPPLY, INC.
	 

	 	MEDICINE MADE EASY
	 

	 	SPECIALTY PHARMACIES, INC.

	 	 	 	 	 
	 	 	 
	 	By:  	/s/ Michael P. Moran
 	 
	 	 	Name:  	Michael P. Moran 	 
	 	 	Title:  	President 	 
	 

	 	 	 
	Agent:

	 	CIT HEALTHCARE LLC, as Agent

	 	 	 	 	 
	 	 	 
	 	By:  	/s/
John Cappellari 	 
	 	 	Name:  	John Cappellari 	 
	 	 	Title:  	Vice President 	 
	 

	 	 	 
	Lenders:

	 	CIT HEALTHCARE LLC, as Lender

	 	 	 	 	 
	 	By:  	/s/
John Cappellari 	 
	 	 	Name:  	John Cappellari 	 
	 	 	Title:  	Vice President 	 
	 

	 	 	 
	 

	 	FIFTH THIRD BANK, as Lender

	 	 	 	 	 
	 	By:  	/s/

Jeffrey A. Thiemann 	 
	 	 	Name:  	Jeffrey A. Thiemann 	 
	 	 	Title:  	Vice President 	 
	 

[SIGNATURE PAGE TO AMENDMENT AND WAIVER AGREEMENT]

S-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]